Who is sponsoring NCT04446052?

NCT04446052 is sponsored by Eastern Cooperative Oncology Group.

What drugs are being tested in NCT04446052?

Interventions in NCT04446052: GM-CSF priming, Placebo.

What condition does NCT04446052 study?

NCT04446052 studies Adult Patients (Over 55) With Acute Non-Lymphocytic Leukemia.

Is NCT04446052 still recruiting?

NCT04446052 is currently completed. Last updated 22 June 2023.

Last reviewed 2023-06-22 · How we verify

NCT04446052

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase III rhu_GM-CSF + 3 Induction Regimens in Adults With Acute Non-Lymphocytic Leukemia

Completed Phase 3 Last updated 22 June 2023

What this trial tests

Phase 3 trial testing GM-CSF priming in Adult Patients (Over 55) With Acute Non-Lymphocytic Leukemia in 362 participants. Completed in 10 July 2002.

Timeline

21 May 1993

Primary endpoint
10 July 2002

10 July 2002

Quick facts

Lead sponsor	Eastern Cooperative Oncology Group
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	362
Start date	21 May 1993
Primary completion	10 July 2002
Estimated completion	10 July 2002

Drugs / interventions tested

GM-CSF priming — full drug profile →
Placebo

Conditions studied

Adult Patients (Over 55) With Acute Non-Lymphocytic Leukemia — all drugs for Adult Patients (Over 55) With Acute Non-Lymphocytic Leukemia →

Sponsor

Eastern Cooperative Oncology Group

Who can join

56 and older, any sex, with Adult Patients (Over 55) With Acute Non-Lymphocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase III Study of Priming with Granulocyte-Macrophage Colony Stimulating Factor (rhu-GM-CSF) and ofThree Induction Regimens in Adult Patients (Over 55) with Acute Non-Lymphocytic Leukemia

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Eastern Cooperative Oncology Group trials

Trials by the same sponsor.

NCT07068074 — A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients · Phase 3 · not yet recruiting
NCT07040280 — Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Pati · Phase 2 · not yet recruiting
NCT07122492 — A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude) · NA · not yet recruiting
NCT07085728 — Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatm · Phase 2 · not yet recruiting
NCT06756607 — The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04446052 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eastern Cooperative Oncology Group
Last refreshed: 22 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04446052.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing